S100A4 and prostate carcinoma: Silencing S100A4 gene expression in endothelial cells by S100A4 small-interfering RNA induces an anti-angiogenic gene signature, and administering S100A4 siRNA into human prostate cancer xenografts significantly decreased tumor vascularity and inhibited tumor growth (151).